Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fenebrutinib Extension Study in Chronic Spontaneous Urticaria
NCT03693625Phase 2Terminated
- Sponsor
- Genentech
- Start
- Sep 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of fenebrutinib in chronic spontaneous urticaria (CSU) (2 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events up to 10 months. Started Sep 2018; status: terminated.
02
Drugs
fenebrutinib
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT03693625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693625.